Clinical Trials Logo

Filter by:
NCT ID: NCT00624468 Terminated - Optic Neuritis Clinical Trials

Atacicept in Subjects With Optic Neuritis

Start date: June 2008
Phase: Phase 2
Study type: Interventional

This study was intended to evaluate the efficacy, safety and tolerability of atacicept compared to placebo and to explore the neuroprotective effect of atacicept as assessed by OCT in subjects with ON as CIS. The study was randomized. Study medication was administered via subcutaneous (under the skin) injections.

NCT ID: NCT00623727 Terminated - Hemophilia A Clinical Trials

BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A

Start date: June 2008
Phase: Phase 2
Study type: Interventional

A study to assess treatment with a new formulation of recombinant factor VIII reconstituted with liposomes (BAY79-4980) to evaluate whether a once-a-week treatment is safe and can prevent bleeds in subjects with severe haemophilia A.

NCT ID: NCT00623415 Terminated - Clinical trials for Relapsing Remitting Multiple Sclerosis

Flupirtine as Oral Treatment in Multiple Sclerosis

FLORIMS
Start date: December 2007
Phase: Phase 2
Study type: Interventional

Flupirtine, a non-opioid analgesic drug, that has been shown to have additional neuroprotective functions, is given twice daily as an oral medication in patients with relapsing remitting multiple sclerosis over a period of 12 months. Neuroprotection is assessed by magnetic resonance imaging, magnetic resonance spectroscopy, optical coherence tomography, and clinical examination.

NCT ID: NCT00622687 Terminated - Systemic Sclerosis Clinical Trials

Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis

ILODOSE
Start date: September 1997
Phase: Phase 2
Study type: Interventional

This study compared the efficacy of different dosages of long-term iloprost treatment on Raynaud's phenomenon, ulcer healing, skin thickening, and progression of internal organ sclerosis in systemic sclerosis (SSc). Methods. 50 SSc patients were 1:1 randomised either for maximally tolerated dose up to 2 ng/kg body weight [bw] per minute or low dose (0.5 ng/kg bw per minute) intravenous iloprost administration, for six hours daily over 21 days. The effect on RP, ulcer healing, skin thickness, oesophagus function, lung involvement as assessed by lung function parameters FVC and DLCO, and side effects were measured. Conclusions. The efficacy of prolonged administration of iloprost is also achieved with low dose iloprost by long term treatment. The effects suggest a disease-modifying capability of iloprost, but further studies are needed to proof this hypothesis.

NCT ID: NCT00622245 Terminated - Clinical trials for Depression in Patients With Bipolar Disorder

Efficacy and Safety of Lu AA34893 in Patients With Bipolar Depression

Start date: January 2008
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of different doses of Lu AA34893 in the treatment of depression in patients with bipolar disorder.

NCT ID: NCT00619229 Terminated - Clinical trials for Macular Degeneration

Alprostadil in Maculopathy Study (AIMS)

Start date: July 2006
Phase: Phase 3
Study type: Interventional

Evaluation of efficacy of alprostadil (prostaglandin E1) for treatment of patients suffering from dry age-related macula degeneration

NCT ID: NCT00618384 Terminated - Clinical trials for Hepatocellular Carcinoma

TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC)

SOCRATES
Start date: January 2008
Phase: Phase 2
Study type: Interventional

For patients with advanced HCC not suitable for resection or liver transplantation but without extrahepatic manifestations, local therapy with TACE is regarded as standard treatment. The present study is planned to evaluate the combination of TACE and sorafenib. A combination of TACE with a multitarget inhibitor like sorafenib may further improve the outcome of patients with HCC.

NCT ID: NCT00617214 Terminated - Schizophrenia Clinical Trials

Schizophrenic Patients Taking Part in Integrated Care Program

CARE I
Start date: January 2008
Phase: N/A
Study type: Observational

Purpose of this non-interventional study (NIS) is to assess the effect of the participation in an integrated care program on treatment outcomes in patients treated with Seroquel for schizophrenia.

NCT ID: NCT00616902 Terminated - Clinical trials for Hypertrophy, Left Ventricular

The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5

PRIMO II
Start date: January 2009
Phase: Phase 3
Study type: Interventional

To evaluate the effects of paricalcitol injection on cardiac structure and function over 48 weeks in subjects with Stage 5 Chronic Kidney Disease (CKD) receiving hemodialysis who have left ventricular hypertrophy (LVH).

NCT ID: NCT00615160 Terminated - Melanoma Clinical Trials

PTK/ZK in Disseminated Malignant Melanoma

Start date: December 2006
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the efficacy of PTK-ZK on metastatic melanoma either as a single agent treatment or in combination with standard chemotherapy according to RECIST criteria. Further to evaluate the safety and tolerability of PTK-ZK in patients with metastatic melanoma either as a single agent treatment or in combination with standard chemotherapy